Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Retrovirology. 2012 Oct 30;9:90. doi: 10.1186/1742-4690-9-90.
HIV-1 Tat activates RNA Polymerase II (RNAP II) elongation of the integrated provirus by recruiting a protein kinase known as P-TEFb to TAR RNA at the 5' end of nascent viral transcripts. The catalytic core of P-TEFb contains CDK9 and Cyclin T1 (CCNT1). A human endogenous complexome has recently been described - the set of multi-protein complexes in HeLa cell nuclei. We mined this complexome data set and identified 12 distinct multi-protein complexes that contain both CDK9 and CCNT1. We have termed these complexes CCAPs for CDK9/CCNT1-associated protein complexes. Nine CCAPs are novel, while three were previously identified as Core P-TEFb, the 7SK snRNP, and the Super-Elongation Complex. We have investigated the role of five newly identified CCAPs in Tat function and viral gene expression.
We examined five CCAPs that contain: 1) PPP1R10/TOX3/WDR82; 2) TTF2; 3) TPR; 4) WRNIP1; 5) FBXO11/CUL1/SKP1. SiRNA depletions of protein subunits of the five CCAPs enhanced Tat activation of an integrated HIV-1 LTR-Luciferase reporter in TZM-bl cells. Using plasmid transfection assays in HeLa cells, we also found that siRNA depletions of TTF2, FBXO11, PPP1R10, WDR82, and TOX3 enhanced Tat activation of an HIV-1 LTR-luciferase reporter, but the depletions did not enhance expression of an NF-κB reporter plasmid with the exception of PPP1R10. We found no evidence that depletion of CCAPs perturbed the level of CDK9/CCNT1 in the 7SK snRNP. We also found that the combination of siRNA depletions of both TTF2 and FBXO11 sensitized a latent provirus in Jurkat cells to reactivation by sub-optimal amounts of αCD3/CD28 antibodies.
Our results identified five novel CDK9/CCNT1 complexes that are capable of negative regulation of HIV-1 Tat function and viral gene expression. Because siRNA depletions of CCAPs enhance Tat function, it is possible that these complexes reduce the level of CDK9 and CCNT1 available for Tat, similar to the negative regulation of Tat by the 7SK snRNP. Our results highlight the complexity in the biological functions of CDK9 and CCNT1.
HIV-1 Tat 通过招募一种已知的蛋白激酶 P-TEFb 到新生病毒转录本 5' 端的 TAR RNA 上,激活整合的前病毒的 RNA 聚合酶 II(RNAP II)延伸。P-TEFb 的催化核心包含 CDK9 和 Cyclin T1(CCNT1)。最近描述了一个人类内源性复合物组 - HeLa 细胞核中多蛋白复合物的集合。我们挖掘了这个复合物数据集,并鉴定了 12 个包含 CDK9 和 CCNT1 的独特的多蛋白复合物。我们将这些复合物命名为 CCAPs,即 CDK9/CCNT1 相关蛋白复合物。其中 9 个是新的,而另外 3 个则以前被鉴定为核心 P-TEFb、7SK snRNP 和超延伸复合物。我们研究了五个新鉴定的 CCAP 在 Tat 功能和病毒基因表达中的作用。
我们检查了包含以下蛋白质亚基的五个 CCAP:1)PPP1R10/TOX3/WDR82;2)TTF2;3)TPR;4)WRNIP1;5)FBXO11/CUL1/SKP1。在 TZM-bl 细胞中,用 siRNA 耗尽这五个 CCAP 的蛋白质亚基增强了 Tat 对整合的 HIV-1 LTR-荧光素酶报告基因的激活。在 HeLa 细胞中使用质粒转染实验,我们还发现 siRNA 耗尽 TTF2、FBXO11、PPP1R10、WDR82 和 TOX3 增强了 HIV-1 LTR-荧光素酶报告基因的激活,但除了 PPP1R10 外,这些缺失并没有增强 NF-κB 报告质粒的表达。我们没有证据表明 CCAP 的缺失会干扰 7SK snRNP 中的 CDK9/CCNT1 水平。我们还发现,siRNA 同时耗尽 TTF2 和 FBXO11 使 Jurkat 细胞中的潜伏前病毒对亚最佳量的 αCD3/CD28 抗体的重新激活变得敏感。
我们的结果确定了五个新的 CDK9/CCNT1 复合物,它们能够负调控 HIV-1 Tat 功能和病毒基因表达。由于 CCAP 的 siRNA 耗尽增强了 Tat 的功能,因此这些复合物可能会降低 Tat 可用的 CDK9 和 CCNT1 水平,类似于 7SK snRNP 对 Tat 的负调控。我们的结果突出了 CDK9 和 CCNT1 生物学功能的复杂性。